Filtered By:
Drug: Rituxan

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 7090 results found since Jan 2013.

Dose-adjusted EPOCH-R vs. R-CHOP in frontline management of Waldeyer's ring diffuse large B-cell lymphoma: a retrospective study from a single institution
CONCLUSION: Compared with patients received R-CHOP, those treated by DA-EPOCH-R had superior PFS, OS, and controlled toxicity in patients with WR-DLBCL.PMID:36780421 | DOI:10.1097/CM9.0000000000002593
Source: Chinese Medical Journal - February 13, 2023 Category: General Medicine Authors: Yuanzheng Liang Xindi Liu Jing Yang Henan Wang Yingshi Piao Liqiang Wei Liang Wang Source Type: research

Drug-Induced Liver Injury due to Biologics and Immune Check Point Inhibitors
Med Clin North Am. 2023 May;107(3):623-640. doi: 10.1016/j.mcna.2022.12.008. Epub 2023 Feb 20.ABSTRACTBiological agents have in the last two decades become very important therapeutic agents, particularly for the treatment of various autoimmune disorders. The most widely used biologics are the tumor necrosis factor-α (TNF-α) receptor antagonists: infliximab, adalimumab, and etanercept. Other commonly used biological agents are interleukin (IL)-1 receptor antagonist (Anakinra), interleukin (IL)-6 receptor antagonist (tocilizumab), and CD20 surface antigen antagonist (rituximab). The current review will however focus on TNF...
Source: The Medical Clinics of North America - March 31, 2023 Category: General Medicine Authors: Fernando Bessone Einar S Bj örnsson Source Type: research

Reverse effect of Semaphorin-3F on rituximab resistance in diffuse large B-cell lymphoma via the Hippo pathway
CONCLUSION: Our study thus defined a previously unknown mechanism of SEMA3F-mediated rituximab resistance through TAZ activation in DLBCL and identified potential therapeutic targets in patients.PMID:37114652 | DOI:10.1097/CM9.0000000000002686
Source: Chinese Medical Journal - April 28, 2023 Category: General Medicine Authors: Qiong Li Naya Ma Xinlei Li Chao Yang Wei Zhang Jingkang Xiong Lidan Zhu Jiali Li Qin Wen Lei Gao Cheng Yang Lingyi Rao Li Gao Xi Zhang Jun Rao Source Type: research

Bing-Neel syndrome with a paravertebral mass
We report a patient who presented with back pain, weakness, lower extremity numbness, and gait disturbance accompanied by immunoglobulin M paraproteinemia and lymphoplasmacytic lymphoma in the bone marrow. Thoracic and lumbar magnetic resonance imaging revealed a long paravertebral mass around the spinal column, but the direct infiltration could not be proven. The patient was diagnosed with possible Bing-Neel syndrome and managed with bendamustine and rituximab. After chemotherapy, the patient's neurological and radiological findings improved. Magnetic resonance imaging should be considered when the Bing-Neel syndrome diag...
Source: The American Journal of the Medical Sciences - July 20, 2023 Category: General Medicine Authors: Daisuke Suzuki Daisuke Sato Kenji Kikuchi Takuma Suzuki Kunie Sugasawa Soichi Saito Fumiaki Uchimura Yoshihiro Suzuki Source Type: research

Significant CA 19-9 Elevation in IgG4-Related Autoimmune Pancreatitis - A Diagnostic Dilemma
We describe the case of a 65-year-old male with history of IgG4-RD, presenting with jaundice and abdominal pain. He was found to have a pancreatic mass with significantly elevated IgG4 162 (2-96 mg/dL and CA19-9 levels 2830 (0-35 U/ml). Patient underwent ERCP and biopsy, which ruled out pancreatic cancer and cholangiocarcinoma. He was diagnosed with IgG4-RD autoimmune pancreatitis (AIP) and sclerosing cholangitis. Treatment with steroids and rituximab resulted in significant improvement in the bilirubin and a dramatic decrease in CA19-9 levels.PMID:37714269 | DOI:10.1016/j.amjms.2023.09.016
Source: The American Journal of the Medical Sciences - September 15, 2023 Category: General Medicine Authors: Larabe Farrukh Muhammad Farhan Akhtar Hafiza Hareem Waqar Ruben Peredo-Wende Source Type: research

Current Medical Treatment of Ocular Mucous Membrane Pemphigoid.
Abstract Ocular mucous membrane pemphigoid (MMP), as a potentially blinding disease, is an indication for systemic immunosuppressive treatment. Immunosuppressive agents are chosen with a "stepladder" approach, beginning with drugs having the fewest side effects. Dapsone, sulfapyridine/sulfasalazine and azathioprine are less successful in controlling inflammation than mycophenolate mofetil (MMF) and methotrexate (MTX). Moreover, compared to other immunosuppressive agents, MMF, followed by MTX, has the lowest rate of discontinuation due to side effects. Cyclophosphamide is the most potent immunosuppressive agent use...
Source: The Ocular Surface - October 1, 2013 Category: Opthalmology Authors: Sobolewska B, Deuter C, Zierhut M Tags: Ocul Surf Source Type: research

Rituximab for ANCA-Associated VasculitidesRituximab for ANCA-Associated Vasculitides
After cyclophosphamide induction, three patients (5%) experienced major relapse on rituximab vs 17 (29%) on azathioprine in an unblinded trial. Medscape Medical News
Source: Medscape Medical News Headlines - November 20, 2014 Category: Consumer Health News Tags: Rheumatology News Source Type: news

Clinical update: B-cell receptor kinase inhibitors in chronic lymphocytic leukemia
Abstract B-cell receptor (BCR) inhibitors represent an exciting new treatment modality in chronic lymphocytic leukemia (CLL). Currently, ibrutinib monotherapy as well as idelalisib in combination with rituximab are approved by the European Medical Agency for the treatment of all patients with relapsed/refractory CLL and for first-line treatment of patients with deletion 17p or TP53 mutation unsuitable for chemoimmunotherapy. The results of ongoing trials with these and other BCR inhibitors are expected to lay the basis for approval in further indications, but have to be awaited. Above all, BCR inhibitors have show...
Source: Memo - Magazine of European Medical Oncology - November 28, 2014 Category: Cancer & Oncology Source Type: research

Rituximab induction therapy, survival benefits, and the increasing selection of radiotherapy as the postinduction treatment in patients with primary mediastinal large B-cell lymphoma
Conclusion Rituximab improved the CR and OS rates of patients with PMBCL, but these improvements may be attributable to the increased use of radiotherapy (which may have also resulted from FDG-PET evaluation).
Source: Journal of the Chinese Medical Association - March 21, 2015 Category: Journals (General) Source Type: research